WOONSOCKET, RI, July 11, 2019 /PRNewswire/ - Abacus Health Products ("Abacus" or the "Company") (CSE: ABCS) today announced new retail purchase orders for its line of CBDMEDIC™ products, which are sold to consumers via retail chains and the company's e-commerce platform.  

  REHOVOT, Israel, July 11, 2019 /PRNewswire/ -- Nova (Nasdaq: NVMI), announced today that it will release its results for the second quarter of 2019 before the Nasdaq market opens on Wednesday, August 7, 2019.Mr. Eitan Oppenhaim, President and Chief Executive Officer, and Mr. Dror David, Chief Financial Offic

DENVER, July 11, 2019 /PRNewswire/ -- NightCare, the only program offering overnight daycare to the babies of sex workers, is expanding to two new locations in Asia. 

Lehi, Utah, July 11, 2019 /PRNewswire/ -- Today Young Living Essential Oils, the world leader in essential oils, celebrates the second annual Internation

REHOVOT, Israel, July 11, 2019 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today that it will release its financial results for the second quarter of 2019 on Wednesday, July 31, 2019.

LONDON, July 11, 2019 /PRNewswire/ -- Smith & Nephew (NYSE: SNN; LSE: SN), the global medical technology business, today announces the results of the first ever prospective clinical trial to evaluate the effectiveness of repairing Horizontal Cleavage Tears (HCTs), one of the most common meniscal tears affecting approximately one-third of patients with this injury.

ALBUQUERQUE, N.M., July 11, 2019 /PRNewswire/ -- Lovelace Biomedical and Exemplar Genetics have teamed together to win a contract from the National Institutes of Health's National Center for the Advancement of Translational Sciences, for the study of Sickle Cell Disease (SCD).  SCD is an autosomal recessive disorder that affects a large number of African-Americ

INDIANAPOLIS, July 11, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the New England Journal of Medicine published positive Phase 3 study results of Emgality® (galcanezumab-gnlm) for the treatment of episodic cluster headache.1 In this study, Emgality reduced the frequency of weekly clus

STOCKHOLM, July 11, 2019 /PRNewswire/ -- The James M. Slater, MD Proton Treatment and Research Center at Loma Linda University Medical Center, US, has chosen the treatment planning system (TPS) RayStation®* to replace its existing systems for photon and proton therapy planning, following a tender process. The James M. Slater,

NEW YORK and TORONTO, July 11, 2019 /PRNewswire/ - CBD For Life (the "Company"), a subsidiary of